Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daprodustat - GlaxoSmithKline

Drug Profile

Daprodustat - GlaxoSmithKline

Alternative Names: 1278863; GSK-1278863; GSK-1278863A

Latest Information Update: 03 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-ischaemics; Antianaemics; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Prolyl hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anaemia
  • Phase II Perioperative ischaemia
  • No development reported Diabetic foot ulcer; Tendon injuries
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 21 Aug 2019 Preregistration for Anaemia in Japan (PO)
  • 21 Aug 2019 GlaxoSmithKline filed an NDA application with the Ministry of Health, Labour and Welfare in Japan for Anaemia
  • 30 Jul 2019 GlaxoSmithKline initiates a phase II trial for Anaemia (Treatment-experienced) in USA (PO) (NCT03457701)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top